Apollo Hospitals Shares Rise on Robust Growth Outlook
Apollo Hospitals Enterprise shares rose more than 2% on September 11, 2023, on a robust growth outlook for the healthcare services provider.
The stock was trading at Rs 5,096.55 at 12:45 pm on the National Stock Exchange, up Rs 111.40, or 2.23%, from the previous day’s close.
The brokerage firm UBS has a “buy” rating on Apollo Hospitals with a target price of Rs 6,050 a share.
UBS said that the occupancy trend in the healthcare industry is improving sequentially and expects Apollo’s core healthcare business to see occupancy improve to 65% in the second quarter from 62% in the April-June quarter.
The stock has a trailing P/E of 109.26x, making it the most expensive stock in absolute terms among its peers.
In the June quarter, Apollo Hospitals reported a 16.38% year-on-year (YoY) increase in its revenue from operations at Rs 4,418 crore. Net profit was down 46.60% YoY to Rs 173 crore. The operating profit margins contracted by 100 basis points on year to 12%.
One basis point is one-hundredth of a percentage point.
Apollo Hospitals is engaged in the business of healthcare services, including operation of hospitals, clinics, and pharmacies.
The company has a strong presence in India and is also expanding its operations in international markets.
The stock is likely to continue to be supported by the robust growth outlook for the healthcare sector.
Related News
- 22 Sep
NBCC shares trade higher on Rs 100 crore work order from SAIL
NBCC shares were trading 3 percent higher on September 22 after the company announced having bagged a work order worth Rs 100 crore from SAIL. This is the fourth order-win announced by the company in this month, the total value of the same being Rs 450 crore. NBCC is a public sector undertaking engaged in the business of construction and real estate development. The company specializes in providing project management, consultancy and engineering services for civil construction, infrastructure development, and real estate projects.
- 22 Sep
Glenmark Pharma stock falls on stake sale in Glenmark Life Sciences
Glenmark Pharma stock fell after the company announced it would sell a 75% stake in its subsidiary Glenmark Life Sciences to Nirma. Analysts expect the stake sale to benefit Glenmark Pharma, as it will transition from a net debt position to a cash surplus position. This is expected to have a positive impact on the company's return ratios over the next two to three years.
- 22 Sep
Berger Paints Shares Hit 52-Week High After Turning Ex-Bonus
Berger Paints shares surged 6% to hit a 52-week high after turning ex-bonus on the record date for the issue of bonus shares in the ratio 1:5. The company posted a net profit of Rs 326.3 crore in the April-June quarter of FY24, up 39% year-on-year, on revenue of Rs 2,739.7 crore, up 10% year-on-year. The company expects to get net cash positive by the end of this fiscal year and expects to end the year with double-digit revenue growth on strong demand outlook.
- 22 Sep
Market Update for September 22, 2023
IdeaForge Tech up 3.4% on order RVNL up 3% on highway MoU JSW Steel up 0.4% on sale ICICI Lombard down 1.6% on CEO exit ICICI Bank down 1% on healthcare investment NHPC up 1.3% on extended additional charge Kalyani Forge up 3.2% on new MD IRB Infra up 2.5% on road project closure
- 22 Sep
Lux Industries Shares Down 3% After Income Tax Raid
Lux Industries shares fell 3% on September 22 after news emerged that the Income Tax department had conducted searches at the company's premises in Kolkata and alleged a tax evasion of Rs 200 crore. The company has confirmed the searches and is extending full support.
Leave a Reply